Breaking News

Unigene Divests SDBG Program

Will focus on proprietary drug development and delivery technology

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Unigene Laboratories has divested its non-core asset, Site Directed Bone Growth (SDBG), by assigning seven patent applications to Kieran Murphy, LLC. In addition, Unigene terminated an exclusive license agreement and consulting agreement with Kieran Murphy, LLC, as well as a license option agreement and research agreement with Yale University. In exchange for the assignment of the patents, Unigene will receive sales royalties in excess of 7% and will receive 40% of any future licensing revenue a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters